1. Scrip
  2. >>Business

Eylea Biosimilar Launch Comes Earlier Than Expected, Putting Regeneron Under Pressure

 
• By Jessica Merrill

Amgen will launch a biosimilar version of Regeneron’s top-selling drug Eylea “at risk” following a US Court of Appeals decision denying an injunction.

(Shutterstock)
Key Takeaways
  • Amgen’s plans to launch a biosimilar version of Regeneron’s Eylea could disrupt the company’s growth strategy.

A sudden move by Amgen to launch a biosimilar version of Regeneron’s blockbuster ophthalmology drug Eylea (aflibercept) will put a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Earnings